CFO of Spyre Therapeutics Switches Between Buy‑Sell‑Buy, Betting on Big‑Picture Gains Amid Volatile Stock

Insider Activity Spotlight: Burrows Scott L’s Recent Moves at Spyre Therapeutics

In a Friday filing, Chief Financial Officer Scott Burrows bought 15 000 shares of Spyre Therapeutics at $87.89, the market price a hair above the $87.88 close on June 24. The purchase follows a string of sales in the past month, including a $87.14 sale of 10 000 shares and a $87.12 sale of 5 000 shares on June 25. While the trade size is modest relative to the company’s $7.5 billion market cap, it signals that the CFO is still confident that the stock’s current valuation reflects a sustainable long‑term upside.

What the Pattern Says About Investor Confidence

Burrows’ trading history is dominated by frequent, small‑to‑medium‑size transactions—both purchases and sales—over the last six months. The most recent cluster of sales, all priced in the mid‑$80s, occurred on June 25, the same day as his buy. Such a “buy‑sell‑buy” rhythm can indicate a tactical approach: buying when the price dips, selling when it peaks, and re‑investing once the trend turns. The CFO’s most recent sale on June 1 (3,100 shares at $72.06) illustrates his willingness to liquidate positions when the stock trades lower, suggesting a focus on capital preservation as well as return generation.

The overall average price paid by Burrows in the past six months has hovered near $70, while the current price sits at $87.89. This spread indicates that he may view the present valuation as attractive compared to the average cost basis of his portfolio. For investors, the CFO’s activity underscores a bullish stance—he is buying shares he believes are undervalued relative to his cost basis, even as he continues to divest a portion of his holdings to maintain liquidity.

Implications for Spyre’s Future

Spyre Therapeutics is a mid‑cap biotech focused on inflammatory bowel disease (IBD) therapeutics. The company’s shares have seen a 21% monthly gain and a 487% year‑to‑date rally, yet the price‑earnings ratio remains negative at –34.45. The CFO’s recent purchases, combined with a high social‑media buzz of 96.83% and a positive sentiment score of +49, suggest that insiders are optimistic about upcoming product milestones or pipeline progress. However, the negative earnings metric and the steep weekly decline of –12.39% highlight that the stock remains volatile and potentially over‑valued to some degree.

If Spyre can deliver on its pipeline and secure regulatory approvals, the CFO’s continued buying could reinforce confidence among shareholders. Conversely, if the company’s clinical data stalls or revenue growth fails to materialize, the pattern of sales may foreshadow a sharper decline.

Burrows Scott L: A Transaction Profile

Burrows has consistently traded between 2 500 and 15 000 shares per transaction. His portfolio size has fluctuated between ~95 000 and ~115 000 shares, suggesting a moderate personal stake that is neither too small to lack influence nor too large to raise regulatory scrutiny. He has also exercised a substantial number of stock options—140 000 shares purchased at zero cost on January 9—showing he is actively engaged in the company’s equity incentive program. Historically, Burrows has sold shares at prices ranging from $14.50 (early 2026) to $87.14 (June 25), reflecting a willingness to capitalize on market highs while maintaining a long‑term perspective.

Takeaway for Investors

The CFO’s recent buying, set against a backdrop of frequent sales, indicates a disciplined, opportunistic trading strategy rather than a single speculative move. For investors, this pattern may signal that insiders see value at current levels and are willing to re‑invest, while also maintaining liquidity to capture upside. Given Spyre’s aggressive growth trajectory and the CFO’s active involvement, a cautiously bullish view may be warranted—especially if upcoming clinical results confirm the company’s pipeline potential. However, the negative earnings figure and high valuation ratios warrant a continued watchful eye on both market sentiment and the company’s financial performance.